维奈克拉在急性髓系白血病中的研究进展

Progress of Venetoclax in Acute Myeloid Leukemia

维奈克拉(venetoclax, VEN)是一种靶向B细胞淋巴瘤-2 (B-cell lymphoma-2, BCL-2)的特异性抑制剂。在急性髓系白血病(acute myeloid leukemia, AML)中,VEN单药表现出良好的耐受性,但是疗效有限。VEN联合低甲基化药物或低剂量阿糖胞苷在AML中取得了显著的疗效,为老年或无法耐受强化化疗的AML患者带来了新的治疗选择。VEN联合强化化疗、靶向治疗和免疫治疗等临床试验的初步结果也表现出良好的疗效,为AML患者提供更多治疗可能。同时,使用VEN引发的不良反应和治疗过程中可能产生的耐药问题也需要关注。本文对VEN在AML中的最新研究进展以及其不良反应和耐药机制进行综述,以期为AML治疗提供更多可行方案。

Venetoclax (VEN) is a specific inhibitor that targets B-cell lymphoma-2 (BCL-2). In acute myeloid leukemia (AML), VEN monotherapy shows good tolerability, but its efficacy is limited. However, when combined with hypomethylating agents or low-dose cytarabine, VEN has shown high effec-tiveness in AML treatment. This combination therapy provides a new opportunity for patients with AML, especially the elderly or those who cannot tolerate intensive chemotherapy. Preliminary re-sults from clinical trials combining VEN with intensive chemotherapy, targeted therapy, and im-munotherapy have also demonstrated good efficacy. These findings offer more treatment options for patients with AML. It is also important to note that adverse reactions and drug resistance may occur due to the use of VEN. This review reports the latest research progress of VEN in AML as well as its adverse reactions and drug resistance mechanisms, aiming to present more viable therapeu-tic options for AML.